Ambrosia Biosciences
Ambrosia Biosciences Inc. is a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. The company aims to deliver safe, effective, and affordable small molecule drugs that transform lives globally, focusing on innovative solutions in the field of metabolic health.
Industries
Nr. of Employees
small (1-50)
Services
End-to-end discovery programs focused on orally administered small-molecule therapeutics for obesity and metabolic disorders, delivered through internal development teams and external partnerships.
End-to-end discovery programs focused on orally administered small-molecule therapeutics for obesity and metabolic disorders, delivered through internal development teams and external partnerships.
Expertise Areas
- Small-molecule drug discovery
- Oral therapeutic development
- Obesity and metabolic disorder therapeutics
- Medicinal chemistry
Key Technologies
- Small-molecule design and synthesis
- Oral formulation considerations
- Lead optimization
- Preclinical pharmacology assays
News & Updates
Ambrosia Biosciences announced a Series A financing round of $25 million, which included a strategic investment by Merck, on December 10, 2024.
On February 19, 2025, Ambrosia Biosciences announced the appointment of Jason Haddock to its Board of Directors.
The company announced its Series A financing on August 20, 2024.
Science Magazine reports on Ambrosia Biosciences' efforts in developing new obesity treatments.
Ambrosia Biosciences announced a Series A financing round of $25 million, which included a strategic investment by Merck, on December 10, 2024.
On February 19, 2025, Ambrosia Biosciences announced the appointment of Jason Haddock to its Board of Directors.
The company announced its Series A financing on August 20, 2024.
Science Magazine reports on Ambrosia Biosciences' efforts in developing new obesity treatments.